CXCL2 and neoplasm: In malignant pleural effusions, methotrexate-packaging tumor cell-derived microparticles induces the recruitment of neutrophils to the pleural cavity via CXCL1 and CXCL2 released from macrophages, followed by recruited neutrophils are activated and release reactive oxygen species and NETs to kill tumor cells (51).